--- canonical_name: Oroxylum indicum alternate_names: Sabroxy, Indian Trumpet Tree, Sonapatha, Shyonaka, Broken Bones Tree, Beko Plant canonical_topic: Oroxylum indicum for Health & Longevity short_topic_lc: oroxylum_indicum creation_date: 2026-0626-0004 creator_ai_fullname: Opus 4.8 --- # Oroxylum indicum for Health & Longevity

Evidence Review created on 06/26/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8 **Also known as:** Sabroxy, Indian Trumpet Tree, Sonapatha, Shyonaka, Broken Bones Tree, Beko Plant ## Motivation *Oroxylum indicum* is a flowering tree native to South and Southeast Asia whose bark, seeds, and young pods have been used for centuries in Ayurvedic and traditional Asian medicine. Its bark is unusually rich in plant pigments called flavonoids — chiefly baicalein, chrysin, and oroxylin A — the same family of compounds prized in other medicinal plants for their antioxidant and anti-inflammatory effects. Modern interest centers on standardized bark extracts marketed as memory and brain-health supplements. The tree carries names like "Broken Bones Tree" because its long, falling pods resemble scattered limbs, and it has long featured in folk remedies for cough, fever, joint complaints, and digestive upset. Early human testing of a standardized bark extract pointed to possible memory benefits in aging adults, sparking attention among those interested in protecting cognition as they age. This review examines what the evidence shows about *Oroxylum indicum* as a tool for healthy aging. It weighs the one human trial against a large body of laboratory and animal research, surveys the proposed mechanisms and the major flavonoids involved, and considers safety, sourcing, and the considerable gaps that remain between traditional use and rigorous clinical proof. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section lists high-level overviews and expert discussions that introduce *Oroxylum indicum* and its key flavonoids for a general, health-focused reader. * [Effects of an Oroxylum indicum Extract (Sabroxy®) on Cognitive Function in Adults With Self-reported Mild Cognitive Impairment](https://pubmed.ncbi.nlm.nih.gov/34531736/) - Lopresti et al., 2021 This is the only published human trial on the herb and the single most important primary source for cognitive claims; it details the dose, the standardized extract used, and the specific memory outcomes that improved. * [Anti-Allergic Effect of Oroxylin A from Oroxylum indicum Using in vivo and in vitro Experiments](https://pubmed.ncbi.nlm.nih.gov/27133260/) - Lee et al., 2016 A primary research article that illustrates one of the plant's traditional respiratory and allergy uses with concrete laboratory and animal data, useful for understanding the anti-inflammatory rationale. * [Baicalein induces apoptosis by inhibiting the glutamine-mTOR metabolic pathway in lung cancer](https://pubmed.ncbi.nlm.nih.gov/38432394/) - Li et al., 2025 A recent primary study on baicalein — the most abundant flavonoid in the bark — that explains in mechanistic detail how the compound interacts with a central nutrient-sensing pathway relevant to both cancer and aging biology. *Note: None of the five prioritized experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension) has published dedicated, high-level content on* Oroxylum indicum *by name — the herb is niche and recently commercialized — so no priority-expert item could be included. Only three eligible high-level items are listed above, fewer than the target of five, because no further qualifying non-systematic-review sources discussing* Oroxylum indicum *specifically could be located from reputable non-encyclopedic outlets; the field is dominated by systematic reviews and primary laboratory papers, which are covered in their own sections. The list was not padded with marginally relevant material.* ## Grokipedia * [Oroxylum indicum](https://grokipedia.com/page/Oroxylum_indicum) - Grokipedia The Grokipedia entry provides a broad botanical, phytochemical, and ethnomedicinal overview of the species, useful as a quick orientation to its taxonomy, distribution, and traditional uses. ## Examine * [Oroxylum indicum benefits, dosage, and side effects](https://examine.com/supplements/oroxylum-indicum/) - Examine Examine's dedicated supplement page summarizes the evidence-graded effects of *Oroxylum indicum*, noting its primary traditional use for type 2 diabetes and insulin sensitivity alongside its emerging cognitive data. ## ConsumerLab No ConsumerLab article exists for *Oroxylum indicum*. ConsumerLab does not currently test or review products containing this botanical, likely reflecting its status as a niche, recently commercialized supplement ingredient. ## Systematic Reviews The following systematic reviews summarize the preclinical and limited clinical evidence for *Oroxylum indicum* and its principal flavonoids. * [A Systematic Review of Evidence-Based Health Benefits of Oroxylum indicum and Its Functional Food Potential](https://pubmed.ncbi.nlm.nih.gov/41154001/) - Nguyen et al., 2025 The most comprehensive and recent synthesis, screening 185 articles under a PRISMA framework; it maps traditional uses against experimental data and explicitly flags the near-total absence of human clinical trials and long-term safety data. * [The Biological Activities and Therapeutic Potentials of Baicalein Extracted from Oroxylum indicum: A Systematic Review](https://pubmed.ncbi.nlm.nih.gov/33276419/) - Nik Salleh et al., 2020 A focused systematic review of 20 studies on baicalein from the plant, cataloguing anti-cancer, anti-diabetic, neuroprotective, and cardioprotective effects while stressing the scarcity of human efficacy data. * [Ethnopharmacologically important highly subsidized Indian medicinal plants: Systematic review on their traditional uses, phytochemistry, pharmacology, quality control, conservation status and future prospective](https://pubmed.ncbi.nlm.nih.gov/37951375/) - Anmol et al., 2024 A systematic review covering several prioritized Indian medicinal plants including *Oroxylum indicum*, valuable for its treatment of quality control, standardization, and conservation concerns relevant to sourcing. * [Modulation of diverse oncogenic signaling pathways by oroxylin A: An important strategy for both cancer prevention and treatment](https://pubmed.ncbi.nlm.nih.gov/35985182/) - Sajeev et al., 2022 A systematic review of oroxylin A's effects across cancer signaling pathways, the most thorough source on the flavonoid most distinctive to *Oroxylum indicum*. ## Mechanism of Action *Oroxylum indicum* is not a single molecule but a botanical whose effects derive from a cluster of flavonoids concentrated in the bark and seeds. The three most studied are baicalein, chrysin, and oroxylin A; standardized extracts are defined by their content of these compounds. Their proposed mechanisms overlap and act on several pathways: * **Antioxidant and anti-lipid-peroxidation activity:** The flavonoids scavenge reactive oxygen species (ROS, unstable oxygen-containing molecules that damage cells) and inhibit lipid peroxidation (oxidative damage to cell-membrane fats). Because oxidative stress contributes to both cognitive decline and broader aging processes, this is a leading candidate mechanism for the observed memory effects. * **Anti-inflammatory signaling:** Baicalein and oroxylin A suppress NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells, a master switch for inflammatory genes), inhibit COX-2 (cyclooxygenase-2, an enzyme that produces inflammatory messengers) and 5-LOX (arachidonate 5-lipoxygenase, another inflammation enzyme), and lower interleukin-6 (a pro-inflammatory signaling protein). Chronic low-grade inflammation is a recognized driver of age-related disease. * **Neurotransmitter modulation:** In laboratory studies, oroxylin A inhibits dopamine reuptake (raising levels of a memory- and motivation-related brain chemical) and acts as an antagonist at the GABA-A receptor (a brake-signal receptor in the brain). Blocking this receptor can increase acetylcholine release in the hippocampus, a region central to memory — a plausible route to the episodic-memory gains seen in the human trial. * **Metabolic and pathway effects:** Baicalein modulates gut microbiota and improves metabolic function in diabetic animals, while chrysin activates the p53 pathway (a tumor-suppressor program that triggers controlled cell death) in cancer cells. Baicalein also inhibits the glutamine–mTOR pathway (mTOR, the mechanistic target of rapamycin, is a central nutrient-sensing regulator of growth and aging) in cancer cells. Competing mechanistic views exist. The human trial measured brain-derived neurotrophic factor (BDNF, a protein that supports neuron growth and survival) as a hypothesized mediator, but found no advantage for the extract over placebo — both groups rose similarly, likely from seasonal and lifestyle factors. This argues against BDNF as the primary driver and shifts emphasis toward the antioxidant, anti-inflammatory, and neurotransmitter routes, none of which has been confirmed in humans. Pharmacologically, the active flavonoids are poorly water-soluble with limited oral bioavailability, undergo extensive phase II metabolism (glucuronidation and sulfation, where the body attaches molecules to aid excretion), and have relatively short systemic exposure — properties that complicate dosing and may explain why high laboratory potencies do not translate cleanly to whole-body effects. ## Historical Context & Evolution * **Original use:** *Oroxylum indicum* is a classical Ayurvedic and traditional Southeast Asian medicine. Its bark (Shyonaka/Sonapatha) is one of the components of the well-known Ayurvedic formulation Dashamula, and the plant was used traditionally for cough, fever, fatigue, sore throat, joint complaints, diarrhea, and wound healing. Young pods are eaten as a vegetable in parts of Thailand, Laos, and northeast India. * **Transition to health optimization:** Modern scientific interest grew once chromatography revealed that the bark is exceptionally rich in baicalein — the same flavonoid that made the unrelated herb *Scutellaria baicalensis* (Chinese skullcap) a research target. As laboratory studies accumulated showing antioxidant, anti-inflammatory, anti-cancer, and neuroprotective activity, the plant moved from a folk remedy toward a candidate "functional food" and nootropic ingredient. Commercial standardization arrived with branded methanolic bark extracts (notably Sabroxy), which fixed the flavonoid content and enabled the first controlled human trial in 2021. * **What the historical research found:** Early ethnopharmacological surveys documented widespread, consistent traditional use across multiple cultures; subsequent laboratory work substantiated several of those uses — antidiabetic, hepatoprotective, anti-inflammatory, and antioxidant effects are now described by reviewers as "strongly supported" by experimental data, while others (skin disorders, malaria, tuberculosis) remain unverified. The historical record is therefore one of partial confirmation rather than wholesale validation or dismissal. * **Evolution of opinion:** The field has shifted from cataloguing in vitro effects toward demanding in vivo and human evidence. The current standing is not settled: a 2025 systematic review describes growing global research interest yet repeatedly emphasizes that obesity models, long-term toxicity, and clinical trials remain major gaps. The single human trial and two newly registered clinical trials mark the beginning, not the conclusion, of human evaluation. ## Expected Benefits The benefits below are framed for proactive, health-focused adults considering a standardized bark extract for cognitive and healthy-aging purposes. The evidence base is overwhelmingly preclinical; only cognitive function has been tested in a single human trial. ### Medium 🟩 🟩 #### Episodic Memory and Cognitive Function in Older Adults The strongest human-relevant benefit. In a 12-week randomized, double-blind, placebo-controlled trial of 82 older adults with self-reported memory complaints, a standardized bark extract (1,000 mg/day) produced significantly greater improvements than placebo in episodic memory — specifically immediate word recall, numeric working memory, and rate of visuospatial learning. Proposed mechanisms include antioxidant protection of memory-related brain regions and oroxylin A's effects on dopamine and GABA signaling. The grade is held to Medium rather than High because this is a single, industry-funded trial with multiple cognitive outcomes that were not all positive and no correction for multiple testing. **Magnitude:** Statistically significant between-group improvements on select episodic-memory tasks over 12 weeks; reported effect sizes were small-to-moderate (Cohen's d typically <0.5), with several other cognitive measures showing no benefit. ### Low 🟩 #### Antidiabetic and Insulin-Sensitizing Effects Multiple animal studies and the herb's strongest traditional-use alignment support glucose-lowering and insulin-sensitizing activity, attributed mainly to baicalein's effects on metabolism and gut microbiota. Examine identifies type 2 diabetes and insulin sensitivity as the plant's primary traditional application. No completed human trial has yet confirmed this, though one is now recruiting. **Magnitude:** Consistent reductions in fasting glucose and improved insulin sensitivity in rodent models; no human quantitative data are available. #### Hepatoprotective (Liver-Protective) Effects In vivo studies report that bark extracts protect liver tissue against chemical and metabolic injury, consistent with traditional use for liver ailments. Baicalein's antioxidant and anti-inflammatory actions are the proposed basis, including effects on liver-fat-driven inflammation. **Magnitude:** Reduced liver enzyme elevations and tissue damage in animal models; no human quantitative data are available. #### Anti-Inflammatory and Antioxidant Activity Robust and consistent across laboratory and animal models, with the flavonoids inhibiting NF-κB, COX-2, and 5-LOX and scavenging reactive oxygen species. This underlies several downstream benefits and the traditional uses for joint, respiratory, and allergic complaints. **Magnitude:** Marked reductions in inflammatory markers and oxidative-stress indices in preclinical models; no human quantitative data are available. #### Cardiovascular and Lipid Effects Animal studies report that extracts protect the heart, reduce arterial plaque buildup, lower blood lipids, and counter oxidative damage, suggesting potential relevance to cardiovascular aging. **Magnitude:** Lowered cholesterol and reduced atherosclerotic burden in rodent models; no human quantitative data are available. ### Speculative 🟨 #### Anti-Cancer and Longevity-Pathway Modulation Baicalein, chrysin, and oroxylin A each show anti-tumor activity in cell and animal studies through pathways relevant to aging, including p53 activation and inhibition of the glutamine–mTOR axis. Oroxylin A modulates numerous cancer-signaling pathways. These findings are mechanistically intriguing for longevity but rest entirely on laboratory and animal work with no human cancer or lifespan data. #### Anti-Osteoporotic and Bone-Protective Effects Oroxin B reduced bone loss in ovariectomized mice by regulating the MAPK (mitogen-activated protein kinase, a cell-signaling cascade controlling growth and stress responses) and NF-κB pathways, and baicalein is associated with bone health in reviews. Relevant to age-related bone loss but confined to animal models. #### Anti-Obesity Effects Oroxylin A inhibits fat-cell formation and promotes fat breakdown in vitro, and the human cognition trial noted a non-significant trend toward minor weight loss. Evidence is limited to cell studies and an incidental observation; no in vivo obesity model has been published. ## Benefit-Modifying Factors * **Baseline cognitive status:** The only human benefit signal appeared in older adults with self-reported mild cognitive complaints. People with no memory concerns or with established dementia may respond differently; the trial specifically excluded diagnosed dementia and selected for mild, subjective impairment. * **Baseline oxidative and inflammatory load:** Because the proposed mechanisms are antioxidant and anti-inflammatory, individuals with higher baseline oxidative stress or chronic inflammation may theoretically derive more benefit, though this has not been tested directly. * **Baseline metabolic status:** The antidiabetic and insulin-sensitizing signals suggest that those with impaired glucose regulation or insulin resistance may be more responsive — the rationale behind a newly recruiting trial combining cognition and insulin-resistance endpoints. * **Age:** Benefits are best characterized at the older end of the adult range (the human trial enrolled older adults). Whether younger, cognitively healthy adults gain measurable benefit is unknown. * **Sex-based differences:** No human data isolate sex effects. The bone-protection animal work used ovariectomized (estrogen-depleted) females, hinting at possible relevance to postmenopausal women, but this is speculative and unconfirmed in humans. * **Genetic factors:** BDNF gene variants and other polymorphisms were noted as uncontrolled confounders in the human trial and could modify cognitive response, but no pharmacogenetic data exist for this botanical. ## Potential Risks & Side Effects Framed for proactive adults: the overall human safety record is thin but reassuring at studied doses, and the main documented effects are mild and gastrointestinal. ### Medium 🟥 🟥 #### Mild Gastrointestinal Complaints The most consistently reported human adverse effect. In the 12-week trial, the extract group showed an increased tendency toward mild digestive complaints (such as stomach upset) compared with placebo. This is consistent with the bark's noted bitterness and the irritant potential of concentrated plant extracts. **Magnitude:** More frequent mild digestive complaints in the active group than placebo over 12 weeks; generally mild and not treatment-limiting in the trial. #### Headache Also more common in the extract group than placebo in the only human trial, though mild. The mechanism is unclear and could relate to the neurotransmitter effects of oroxylin A. **Magnitude:** Modestly increased frequency of mild headache versus placebo over 12 weeks. ### Low 🟥 #### Unconfirmed Long-Term and Chronic Toxicity The single human trial lasted only 12 weeks, and preclinical safety studies were mostly limited to 28 days or less. Reviewers explicitly flag the absence of chronic, reproductive, and developmental toxicity data. The risk here is uncertainty rather than a demonstrated harm: long-term safety is simply unknown. **Magnitude:** No long-term human data; preclinical exposure generally ≤28 days, so chronic risk cannot be estimated. ### Speculative 🟨 #### Theoretical Drug-Metabolism Interactions The flavonoids in *Oroxylum indicum* are structurally similar to compounds known to influence drug-metabolizing enzymes, raising a theoretical possibility of altering the levels of co-administered medications. No human interaction studies exist, so this remains a mechanistic concern only. #### Theoretical Bleeding or Antiplatelet Effects Some flavonoids in the baicalein family have mild antiplatelet activity in laboratory settings. Whether *Oroxylum indicum* meaningfully affects bleeding risk in humans is untested and speculative. #### Theoretical Hormonal Activity Certain flavonoids interact weakly with estrogen-related pathways. No evidence of clinically meaningful hormonal effects from *Oroxylum indicum* exists in humans, but the possibility has not been excluded. ## Risk-Modifying Factors * **Genetic factors:** Polymorphisms in flavonoid-metabolizing enzymes — chiefly the UGT and SULT families (UGT1A and SULT1A, which attach molecules to flavonoids to aid their excretion) and CYP enzymes (the liver's main drug-processing enzymes) — could in principle alter how quickly the active flavonoids are cleared and therefore shift both exposure and the theoretical drug-interaction risk. No pharmacogenetic data exist for *Oroxylum indicum*, so this remains a mechanistic consideration rather than an established modifier. * **Concurrent medications:** Individuals taking drugs with narrow safety margins (such as blood thinners or medications heavily processed by the liver) face the greatest theoretical interaction risk, given the flavonoids' potential to affect drug metabolism and platelet function. * **Baseline gastrointestinal sensitivity:** Those prone to dyspepsia or with sensitive stomachs may be more likely to experience the mild digestive complaints reported in the trial, particularly given the extract's bitterness. * **Pregnancy and lactation:** No reproductive or developmental safety data exist. This represents a population in whom risk cannot be characterized and for whom use is therefore not supported by evidence. * **Pre-existing liver disease:** While the herb shows hepatoprotective effects in animals, concentrated botanical extracts can occasionally stress the liver in humans; those with existing liver disease lack any safety data specific to this product. * **Age:** The only human safety data come from older adults, in whom the extract was well tolerated over 12 weeks. Safety in younger adults is presumed similar but untested. * **Sex-based differences:** No human data distinguish adverse-effect rates by sex. ## Key Interactions & Contraindications * **Anticoagulant and antiplatelet drugs (warfarin, clopidogrel, aspirin):** Theoretical additive bleeding risk from the flavonoids' mild antiplatelet activity. **Severity: caution.** Consequence: potential increased bleeding. Mitigation: avoid combining without medical supervision; monitor for bruising or bleeding. * **Drugs metabolized by the liver (CYP-substrate medications):** Flavonoids in this family can theoretically inhibit drug-metabolizing enzymes, potentially raising blood levels of co-administered drugs (e.g., certain statins, some immunosuppressants). **Severity: caution.** Consequence: altered drug levels. Mitigation: separate timing and monitor where a narrow-margin drug is involved. * **Antidiabetic drugs (metformin, sulfonylureas, insulin):** Given the herb's glucose-lowering activity, additive blood-sugar lowering is plausible. **Severity: monitor.** Consequence: low blood sugar (hypoglycemia). Mitigation: monitor blood glucose if combining. * **Over-the-counter NSAIDs (nonsteroidal anti-inflammatory drugs, common pain and fever relievers; ibuprofen, naproxen):** Both NSAIDs and the herb act on inflammatory enzymes; combined use is not known to be harmful but could theoretically increase gastrointestinal irritation. **Severity: monitor.** Consequence: stomach upset. Mitigation: take with food. * **Sedatives and GABA-active substances (benzodiazepines, alcohol):** Oroxylin A is a GABA-A receptor antagonist, which could theoretically oppose or interact with sedating drugs. **Severity: caution.** Consequence: unpredictable change in sedative effect. Mitigation: avoid combining pending data. * **Other blood-sugar-lowering supplements (berberine, cinnamon, alpha-lipoic acid):** Additive glucose-lowering effect possible. **Severity: monitor.** Consequence: hypoglycemia. Mitigation: monitor glucose. * **Populations who should avoid the intervention:** Pregnant and breastfeeding women (no safety data); children (no data); individuals scheduled for surgery within 2 weeks (theoretical bleeding risk); people with known hypersensitivity to the plant or to baicalein-containing botanicals. ## Risk Mitigation Strategies * **Start at a single daily dose:** Begin with 500 mg once daily rather than the full 1,000 mg/day used in the trial, to gauge gastrointestinal tolerance before increasing — directly reducing the mild digestive complaints and headache that were the main reported effects. * **Take with food:** Administering the extract with a meal can buffer the bitterness-related stomach irritation and the theoretical additive irritation when combined with NSAIDs. * **Pause before surgery:** Discontinue at least 2 weeks before any scheduled surgery to address the theoretical antiplatelet/bleeding risk from the flavonoids. * **Monitor blood glucose if diabetic:** Given the herb's glucose-lowering activity, those on antidiabetic medication should check blood sugar regularly to catch additive hypoglycemia early. * **Separate from narrow-margin medications:** For anyone taking blood thinners or drugs with narrow safety windows processed by the liver, separate dosing in time and seek medical oversight to mitigate the theoretical drug-metabolism interaction. * **Limit duration pending data:** Because chronic safety is unproven, restricting continuous use to studied durations (around 12 weeks) with breaks addresses the unknown long-term toxicity risk. ## Therapeutic Protocol * **Standard protocol:** The only evidence-based human protocol comes from the 2021 trial: 500 mg of a standardized methanolic bark extract (Sabroxy, standardized to 10% oroxylin A, 6% chrysin, 15% baicalein) taken twice daily, totaling 1,000 mg/day, for 12 weeks. This is the de facto reference used by supplement formulators. * **Competing approaches:** There is no established conventional medical protocol — *Oroxylum indicum* is not an approved drug. The main alternatives are whole-bark traditional Ayurvedic preparations (decoctions, often within multi-herb formulas like Dashamula) versus modern standardized single-herb extracts. Standardized extracts are favored in the research context because they fix flavonoid content; traditional decoctions vary widely and are not dose-defined. Neither is framed here as superior. * **Expert/origin attribution:** The 1,000 mg/day standardized-extract protocol was popularized by Sabinsa/Sami-Sabinsa (the maker of Sabroxy) and tested by Lopresti and colleagues at Clinical Research Australia; this commercial origin is a relevant conflict of interest discussed in the Conclusion. * **Best time of day:** The trial used morning and evening dosing with or without food. Because oroxylin A affects dopamine and GABA signaling (potentially alerting), morning dosing may be theoretically preferable for those sensitive to stimulation, though no timing study exists. * **Half-life:** The active flavonoids have relatively short systemic exposure and undergo rapid phase II metabolism, which is the rationale for twice-daily rather than once-daily dosing. * **Single vs. split dose:** The evidence-based protocol splits the dose (twice daily), consistent with the short half-life of the flavonoids; single daily dosing has not been studied for efficacy. * **Genetic considerations:** No pharmacogenetic data guide dosing. BDNF polymorphisms were noted as a potential confounder of cognitive response but are not actionable for protocol selection. * **Sex-based differences:** No human data support sex-specific dosing. * **Age considerations:** The protocol is validated only in older adults; the same dose is presumed for the broader adult target audience but is untested in younger people. * **Baseline biomarkers:** No biomarker is established to predict or guide dosing; BDNF did not track with response in the trial. * **Pre-existing conditions:** Those with diabetes or on hepatically cleared medications may warrant lower starting doses and closer monitoring, as noted in the interactions section. ## Discontinuation & Cycling * **Lifelong vs. short-term:** No evidence supports lifelong use; the only human data cover a 12-week course. Use is best regarded as a defined trial period rather than an indefinite regimen until long-term safety and durability of effect are established. * **Withdrawal effects:** No withdrawal syndrome has been reported. Given the short half-life and lack of dependence-forming mechanisms, abrupt cessation is not expected to cause physical withdrawal. * **Tapering:** No tapering protocol is needed or described; the extract can be stopped without a taper based on available data. * **Cycling:** No cycling regimen has been formally studied. Periodic breaks are a reasonable precaution given the absence of chronic-toxicity data, but there is no evidence that cycling preserves efficacy or that tolerance develops. * **Durability of benefit:** Whether cognitive gains persist after stopping is unknown — the trial did not include a follow-up phase after the 12-week treatment period. ## Sourcing and Quality * **Standardization is paramount:** Because the plant's effects depend on its flavonoid content, the single most important quality factor is a defined standardization (the trial extract was standardized to 10% oroxylin A, 6% chrysin, 15% baicalein). Unstandardized "whole bark" powders provide no assurance of active content. * **Plant part and extract type:** Evidence supports the bark, prepared as a methanolic extract. Products using other plant parts (leaf, seed, pod) or different solvents are not interchangeable with the studied material and lack human data. * **Third-party testing:** Look for products with independent testing for identity, flavonoid content, and contaminants. Botanical supplements are prone to adulteration and heavy-metal or pesticide contamination; conservation pressure on wild *Oroxylum indicum* also raises the risk of substitution with other species. * **Reputable sources:** The only clinically tested branded extract is Sabroxy (Sabinsa/Sami-Sabinsa); products built on this branded ingredient most closely match the evidence. This is noted not as an endorsement but because it is the sole material with human data, and the supplier has a direct commercial interest. * **Species verification:** Given documented conservation and substitution concerns, sourcing from suppliers who verify botanical identity (e.g., by chromatographic fingerprinting) reduces the risk of receiving a misidentified or adulterated product. ## Practical Considerations * **Time to effect:** In the only human trial, cognitive benefits were assessed at 12 weeks; no earlier timepoint was reported, so the realistic expectation is a multi-week course before any effect, not acute improvement. * **Common pitfalls:** Using unstandardized bark powder and expecting trial-level results; assuming the strong laboratory potency of baicalein translates to whole-body effects despite poor bioavailability; treating preclinical anti-cancer or longevity findings as if they were human-proven; and exceeding the studied 1,000 mg/day dose in pursuit of greater effect. * **Regulatory status:** *Oroxylum indicum* is sold as a dietary supplement, not an approved drug, in most markets including the US and EU. It is not subject to pre-market efficacy approval, and any health claims are unverified by regulators. All cognitive use is, in effect, off-label self-experimentation. * **Cost and accessibility:** Standardized branded extracts are moderately priced and widely available online; the herb is neither exceptionally expensive nor difficult to obtain, so cost is not a major barrier. ## Interaction with Foundational Habits * **Sleep:** The interaction is plausibly **direct** but undefined. Oroxylin A's antagonism of the GABA-A receptor (the brain's main calming-signal receptor) could theoretically be alerting and disrupt sleep if taken late in the day; no sleep study exists. As a practical consideration, evening dosing could be shifted earlier if sleep is affected. * **Nutrition:** The interaction is **indirect**. The flavonoids are poorly water-soluble, so taking the extract with a fat-containing meal may modestly aid absorption, and food buffers the bark's bitterness and gastrointestinal irritation. No specific diet is required or contraindicated; the antidiabetic signal suggests possible synergy with a low-glycemic eating pattern, though this is unproven. * **Exercise:** The interaction appears **none-to-indirect** and is essentially unstudied. There is no evidence the extract blunts or enhances training adaptations. The antioxidant activity raises a purely theoretical concern that, like other strong antioxidants, it could blunt some exercise-induced signaling, but no data support this for *Oroxylum indicum*. * **Stress management:** The interaction is plausibly **indirect** via neurotransmitter effects. Oroxylin A's actions on dopamine and GABA signaling could theoretically influence mood and stress response — the human trial noted self-reported mood improvement — but no study has measured cortisol or formal stress outcomes, so practical guidance is not yet possible. ## Monitoring Protocol & Defining Success Before starting, a brief baseline assessment helps establish whether the extract is producing meaningful change, since the documented benefits are subtle and the safety data are limited. Baseline testing should capture liver function, glucose regulation, and a standardized cognitive measure so that change can be detected objectively rather than by impression alone. Ongoing monitoring should follow a simple cadence: re-check liver enzymes and fasting glucose at roughly 6–12 weeks if combining with hepatically cleared or antidiabetic medications, and reassess cognitive measures at the 12-week mark that matches the trial's evaluation point, then every 3–6 months if continued. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | ALT / AST (liver enzymes) | ALT <25 U/L (men), <20 U/L (women); AST <25 U/L | Detect any liver stress from a concentrated botanical extract | Conventional upper limits (~40 U/L) are higher than functional targets; fasting not required; recheck at 6–12 weeks if on liver-cleared drugs | | Fasting glucose | 75–90 mg/dL | Track the herb's glucose-lowering activity and catch additive hypoglycemia | Requires 8–12 h fast; pair with HbA1c (glycated hemoglobin, a marker of average blood sugar over ~3 months) for a fuller picture | | HbA1c | <5.4% | Assess longer-term glucose control given antidiabetic signal | No fasting needed; reflects ~3 months of glucose; best paired with fasting glucose | | hs-CRP (inflammation marker) | <1.0 mg/L | Gauge whether anti-inflammatory effects translate to a measurable change | Avoid testing during acute illness; conventional "low risk" cutoff (<3.0 mg/L) is looser than functional target | | Complete blood count (CBC) | Within standard reference ranges | Screen for any unexpected hematologic effect during longer use | Useful as a general safety check; no fasting required | Qualitative markers matter as much as labs for a cognitive-aimed intervention and should be tracked subjectively: * **Memory and recall:** noticeable ease in recalling names, words, and recent events — the domain that improved in the trial. * **Mental clarity and focus:** subjective sharpness or "brain fog" reduction during daily tasks. * **Mood:** the trial noted self-reported mood improvement; track for better or worse changes. * **Sleep quality:** watch for any disruption, given the theoretical alerting effect of evening dosing. * **Digestive comfort:** track stomach upset, the most common reported side effect, to decide on dose or timing adjustments. ## Emerging Research The research frontier for *Oroxylum indicum* is shifting from laboratory work toward its first dedicated human trials, with studies that could either strengthen or weaken the current cognitive and metabolic case. * **Ongoing cognition and insulin-resistance trial:** A study titled "Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairment and Insulin Resistance" ([NCT07220694](https://clinicaltrials.gov/study/NCT07220694)) is currently recruiting, with a planned enrollment of 140 participants. It directly tests both the cognitive and the metabolic signals in a single population and could substantially strengthen — or fail to replicate — the existing findings. * **Completed second cognition trial:** A study titled "A Study of Sabroxy™ (Oroxylum indicum Extract) for Improving Cognitive Function in Adults With Mild Memory Concerns" ([NCT07189754](https://clinicaltrials.gov/study/NCT07189754)) has been completed with 70 participants. Its results, once published, will be the first independent test of whether the 2021 memory findings replicate. * **Baicalein influenza trial:** A Phase 2a randomized, placebo-controlled trial of baicalein tablets in influenza fever ([NCT03830684](https://clinicaltrials.gov/study/NCT03830684)), with 180 planned participants, tests the lead flavonoid's anti-inflammatory and antiviral activity in humans — relevant to the plant's traditional respiratory uses, though the status is listed as unknown. * **Replication and independence as a key question:** The decisive future research need is independent, adequately powered replication of the cognitive benefit without industry funding, with correction for multiple comparisons and a post-treatment follow-up to test durability — directly addressing the main weaknesses of the Lopresti et al., 2021 trial ([PMID 34531736](https://pubmed.ncbi.nlm.nih.gov/34531736/)). * **Bioavailability and formulation:** Because the active flavonoids are poorly absorbed, research into improved delivery (e.g., the eco-friendly extraction and nanoformulation approaches catalogued by Nguyen et al., 2025, [PMID 41154001](https://pubmed.ncbi.nlm.nih.gov/41154001/)) could change effective dosing and either amplify benefits or unmask new safety signals. * **Long-term safety and metabolic models:** Future toxicology beyond 28 days and the still-missing in vivo obesity models flagged by reviewers will determine whether the speculative metabolic benefits hold and whether chronic use is safe. ## Conclusion *Oroxylum indicum* is a traditional South and Southeast Asian medicinal tree whose bark is rich in flavonoids — chiefly baicalein, chrysin, and oroxylin A — now sold as a standardized extract aimed at memory and healthy aging. Its most credible benefit for the proactive, longevity-minded adult is a modest improvement in memory in older people with mild cognitive complaints, seen over twelve weeks. A wider set of possible benefits — better blood-sugar control, liver protection, reduced inflammation, heart and bone support, and effects on cancer-related pathways — rests almost entirely on cell and animal studies and should be read as promising leads rather than proven outcomes. The quality of the evidence is the central caveat. Human data come from a single, small study funded by the maker of the extract, with several memory measures showing no benefit and no long-term safety information. Side effects appear mild, mainly stomach upset and headache, but chronic safety is genuinely unknown. The flavonoids are also poorly absorbed, so strong laboratory effects may not carry over to the whole body. For now, the memory signal is real but preliminary, and most of the broader longevity case remains unconfirmed and uncertain. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**